O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases
Clinical Trial Application approval…Read More
You might also be interested in reading Brokers Gain Multi Asset Liquidity Access as X Securities Joins Centroid.